NCT06775665Recruiting
A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population
Clinical Characteristics and Real-World Outcomes of Chinese Patients With Hypertrophic Cardiomyopathy: A Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 9 Jan 2025
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Jan 2031
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06775665
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 1 Jun 2026 to the primary completion date, 1 Jan 2031
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled primary hypertension.
- Moderate or severe aortic valve stenosis and/or primary mitral valve disease with severe mitral regurgitation.
- Confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., Fabry disease, amyloidosis).
- Severe infections, liver failure, renal failure, or other life-threatening conditions.
Age
- Expected life expectancy \<1 years.
Who the study is looking for
- Willing and able to provide written informed consent (ICF) and any required privacy authorization before the start of the study.
- Aged ≥18 years at the time of signing the written informed consent.
- Diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, meeting the following criteria:
- Left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (MRI).
- Left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family.
- Exclusion of other cardiovascular diseases or systemic/metabolic diseases causing ventricular wall thickening.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China Coordinator of this site? Confirm its status | Hangzhou | China | Not yet recruiting |
| Second Affiliated Hospital, Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.